Small Is­raeli biotech flops a PhI­II test in post-surgery in­fec­tions — shares crushed

A small Is­raeli biotech try­ing to de­vel­op a treat­ment to re­duce in­fec­tions stem­ming from surgery faced se­ri­ous in­vestor back­lash Fri­day af­ter a Phase III fail.

PolyPid had been work­ing on a pro­gram called D-Plex100 in a piv­otal study for sur­gi­cal site in­fec­tions (SSIs) af­ter ab­dom­i­nal surgery. And al­though the can­di­date de­creased in­fec­tions and death com­pared to stan­dard of care, the dif­fer­ences were not sta­tis­ti­cal­ly sig­nif­i­cant.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER